Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.66 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
| ▸ | PIM1 | P11309 | 13/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041644 | 0.94 | MKNK1 (0.73) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3041642 | 0.94 | MKNK1 (0.73) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3036609 | 0.85 | MKNK1 (0.88) | MKNK1FYNPIM1KCNH2 | |
| SCHEMBL3027620 | 0.85 | MKNK1 (0.72) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3037817 | 0.85 | MKNK1 (0.72) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3037826 | 0.83 | MKNK1 (0.73) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3037832 | 0.83 | MKNK1 (0.73) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3036741 | 0.83 | MKNK1 (0.69) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3036739 | 0.83 | MKNK1 (0.69) | MKNK1FYNPIM1KCNH2IKBKB | |
| SCHEMBL3039245 | 0.82 | FYN (0.79) | MKNK1FYNPIM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | MKNK1 816/4885FYN 3/4885PIM1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.